GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (NAS:NAOV) » Definitions » Quick Ratio

NanoVibronix (NanoVibronix) Quick Ratio : 1.53 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is NanoVibronix Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. NanoVibronix's quick ratio for the quarter that ended in Dec. 2023 was 1.53.

NanoVibronix has a quick ratio of 1.53. It generally indicates good short-term financial strength.

The historical rank and industry rank for NanoVibronix's Quick Ratio or its related term are showing as below:

NAOV' s Quick Ratio Range Over the Past 10 Years
Min: 0.02   Med: 2.2   Max: 5.74
Current: 1.53

During the past 13 years, NanoVibronix's highest Quick Ratio was 5.74. The lowest was 0.02. And the median was 2.20.

NAOV's Quick Ratio is ranked worse than
60.74% of 866 companies
in the Medical Devices & Instruments industry
Industry Median: 2.055 vs NAOV: 1.53

NanoVibronix Quick Ratio Historical Data

The historical data trend for NanoVibronix's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoVibronix Quick Ratio Chart

NanoVibronix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.20 2.70 4.29 1.48 1.53

NanoVibronix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.48 1.03 0.21 1.67 1.53

Competitive Comparison of NanoVibronix's Quick Ratio

For the Medical Devices subindustry, NanoVibronix's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoVibronix's Quick Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoVibronix's Quick Ratio distribution charts can be found below:

* The bar in red indicates where NanoVibronix's Quick Ratio falls into.



NanoVibronix Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

NanoVibronix's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(6.487-2.732)/2.454
=1.53

NanoVibronix's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(6.487-2.732)/2.454
=1.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NanoVibronix  (NAS:NAOV) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


NanoVibronix Quick Ratio Related Terms

Thank you for viewing the detailed overview of NanoVibronix's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NanoVibronix (NanoVibronix) Business Description

Traded in Other Exchanges
Address
525 Executive Boulevard, Elmsford, New York, NY, USA, 10523
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.
Executives
Christopher M Fashek director 8023 VANTAGE DR, SAN ANTONIO TX 78230
Stephen Russell Brown officer: Chief Financial Officer 18-B NEIL COURT, OCEANSIDE NY 11572
Aurora Cassirer director C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Maria Schroeder director C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Brian M Murphy director, officer: Chief Executive Officer 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Michael Ferguson director 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Thomas Mika director TEGAL CORP, 2201 SOUTH MCDOWELL BLVD, PETALUMA CA 94954
Ira A Greenstein director IDT CORP, 520 BROAD STREET, NEWARK NJ 07102
Harold Jacob director, officer: Chief Medical Officer HAADMUR MEBUYON 26, HARNOT, JERUSALEM L3 95403
Martin M Goldstein director C/O NANOVIBRONIX, INC., 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
William Stern director, officer: Chief Executive Officer 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Jona Zumeris director, officer: VP of Technology 105 MAXESS ROAD, SUITE S124, MELVILLE NY 11747
Miriam W Kelly 10 percent owner P.O. BOX 1443, BROOKLANDVILLE MD 21022